Dr. Taneja Discusses Multiparametric MRI in Prostate Cancer

Samir Taneja, MD
Published: Friday, Feb 02, 2018



Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.

The advent of multiparametric MRI has allowed radiation oncologists to use different functional sequences to better assess the prostate and determine the severity of the cancer. In an additional effort to better image the prostate, Taneja says that pre-biopsy MRI is an innovative technique used at NYU Langone. This technique provides the opportunity to better monitor the disease than with fewer biopsies.

More precise imaging techniques allow physicians to better diagnose, risk-assess, localize, and choose treatments for prostate cancer more accurately. Prior data published in the Journal of Urology showed that MRI-guided biopsies were 3 times as likely to identify cancer compared with traditional biopsies. This has resulted in a reduction of side effects for many patients whose cancer is lower-risk, as imaging can spare them from conventional therapy.
 


Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.

The advent of multiparametric MRI has allowed radiation oncologists to use different functional sequences to better assess the prostate and determine the severity of the cancer. In an additional effort to better image the prostate, Taneja says that pre-biopsy MRI is an innovative technique used at NYU Langone. This technique provides the opportunity to better monitor the disease than with fewer biopsies.

More precise imaging techniques allow physicians to better diagnose, risk-assess, localize, and choose treatments for prostate cancer more accurately. Prior data published in the Journal of Urology showed that MRI-guided biopsies were 3 times as likely to identify cancer compared with traditional biopsies. This has resulted in a reduction of side effects for many patients whose cancer is lower-risk, as imaging can spare them from conventional therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x